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http://www.biomedcentral.com/1756-0500/7/496CASE REPORT Open AccessLong-term tumor control of spinal dissemination
of cerebellar glioblastoma multiforme by
combined adjuvant bevacizumab antibody
therapy: a case report
Thomas Linsenmann1*, Camelia M Monoranu2, Giles H Vince3, Thomas Westermaier1, Carsten Hagemann1,
Almuth F Kessler1, Ralf-Ingo Ernestus1 and Mario Löhr1Background: Glioblastoma multiforme located in the posterior fossa is extremely rare with a frequency up to 3.4%.
Compared with glioblastoma of the hemispheres the prognosis of infratentorial glioblastoma seems to be slightly
better. Absence of brainstem invasion and low expression rates of epidermal growth factor receptor are described
as factors for long-time survival due to the higher radiosensitivity of these tumors.
Case presentation: In this case study, we report a German female patient with an exophytic glioblastoma
multiforme arising from the cerebellar tonsil and a secondary spinal manifestation. Furthermore, the tumor
showed no O (6)-Methylguanine-DNA methyltransferase promotor-hypermethylation and no isocitrate dehydrogenase 1
mutations. All these signs are accompanied by significantly shorter median overall survival. A long-term tumor control of
the spinal metastases was achieved by a combined temozolomide/bevacizumab and irradiation therapy, as part of a
standard care administered by the treating physician team.
Conclusion: To our knowledge this is the first published case of a combined cerebellar exophytic glioblastoma with a
subsequent solid spinal manifestation. Furthermore this case demonstrates a benefit undergoing this special adjuvant
therapy regime in terms of overall survival. Due to the limited overall prognosis of the disease, spinal manifestations of
glioma are rarely clinically relevant. The results of our instructive case, however, with a positive effect on both life quality
and survival warrant treating future patients in the frame of a prospective clinical study.
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Glioblastoma mulitforme (GBM) is the most common
primary tumor of the central nervous system (CNS)
comprising approximately 50% of all primary intracranial
tumors [1]. It is located most frequently in the cerebral
hemispheres and the peak age of onset is the sixth or
seventh decade. GBM located in the cerebellum is ex-
tremely rare with a frequency of 0% to 3.4% [2-5]. The
standard treatment is surgical tumor excision to the ex-
tent feasible, followed by radiotherapy and temozolo-
mide chemotherapy [6,7]. Compared to GBM of the
hemispheres, the prognosis of infratentorial GBM* Correspondence: Linsenmann_T@ukw.de
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article, unless otherwise stated.seems to be slightly better. Absence of brainstem inva-
sion and a low expression rate of epidermal growth
factor receptor (EGFR) are described as factors for
long–time survival due to the higher radiosensitivity of
these tumors [8,9].
Extracranial metastasis from GBM is rare, with a re-
ported frequency of only 0.44%. In the reported cases, me-
tastases occurred in regional lymph nodes, lungs, pleura,
and occasionally in the bone and liver. Spinal metastases
are clinically rarely detected [10]. Spinal cord involvement
can be due to a leptomeningeal or vertebral localization,
whereas intraparenchymal metastasis of the myelon is ex-
tremely rare. Although involvement of the spinal cord hasntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Preoperative (a) axial and (b) sagittal T1-weighted
magnetic resonance imaging after gadopentetate dimeglumine
application, demonstrating a well-defined enhancing mass
located dorsal from the medulla oblongata with
brainstem attachment.
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literature provides 42 documented cases [11].
Case presentation
A 55-year-old German woman presented at our depart-
ment with a short history of persistent headache, vertigo,
nausea, and a generalized seizure. Magnetic resonance
imaging (MRI) showed a well-defined tumor approximately
1.7 × 3.7 × 2.6 cm in size, located at the cranio-cervical
junction with dorsal compression of the medulla oblon-
gata, and in close relation to the right vertebral artery.
The tumor was hyperintense on T2-weighted images and
displayed an intense, nearly homogeneous gadolinium (Gd)
enhancement. Due to its close contact to the dura,
the initial tentative neuroradiological diagnosis was an
infratentorial meningioma [Figure 1]. The tumor was
completely removed via a median suboccipital craniot-
omy, opening of the foramen magnum, and resection of
the dorsal arch of C1. Microsurgical complete excision of
the tumor was achieved by the aid of electrophysiologicalFigure 2 Histological examination on formalin fixed and paraffin emb
microvascular proliferation (H&E, x100); b) immunohistochemistry for glial f
c) high proliferation as determined by the antibody Ki67 (x100); d) lack of e
magnification (x200) colon carcinoma as positive control (inset).monitoring (Electromyographies (EMG) of the lower cra-
nial nerves, somatosensory evoked potentials (SEP) and
motoric-evoked potentials of the medianus nerve (MEP)).
The histological examination on formalin fixed and
paraffin embedded tissue confirmed the diagnosis of a
glioblastoma multiforme WHO IV with a typical high
cellular pleomorphism, microvascular proliferations, and
necrotic areas [Figure 2] but without EGFR-expression.
Immunhistochemistry also showed a missing MGMT O
(6)-Methylguanine-DNA methyltransferase promotor-
hypermethylation (MGMT) and no isocitrate dehydro-
genase 1 mutation (IDH1).
The postoperative course of the patient was unevent-
ful. She underwent radiochemotherapy with an over-all
dose of 54 Gy applied in fractions of 1,8 Gy twice a day
over a period of 3 weeks and concomitant temozolomide
chemotherapy (75 mg/m2 body surface). Adjuvant temo-
zolomide chemotherapy according to the Stupp regimen
(200 mg/m2 body surface) [8] was administered 12 times.
After 15 months without new tumor progression MRIs
showed in the area of the right cerebellar tonsil a relapse
of about 1.4 × 1.9 × 1.6 cm in size.
She underwent a second operation, but because the
tumor had infiltrated the cranial nerves IX and X only a
subtotal tumor resection could be performed.
The histological examination confirmed GBM with high
mitotic rate and again negative MGMT methylation.
Two weeks later, the patient described lower limb pain,
reduced sensitivity, and micturition disorders accompan-
ied by progressive dysphagia. The spinal MRI revealed a
small tumor located dorsal to the 4th lumbar vertebral
body and a large spinal tumor manifestation dorsal to L5
to S1 of approximately 4.0 × 1.2 cm in the sagittal plane
accompanied by multiple gadolinium – enhancing (gd)
nodules throughout the whole spinal column [Figure 3].
Diagnosis of a meningeosis carcinomatosa was confirmed
by the histological results of a spinal tap.edded tissue. a) Glioblastoma with high cellular pleomorphism and
ibrillary acidic protein shows strong expression in tumor cells (x100);
pidermal growth factor receptor in glioblastoma cells (x100); in higher
Figure 3 Sagittal T1-weighted magnetic resonance images
enhanced with gadopentetate dimeglumine demonstrating
spinal tumor located dorsal of lumbar vertebral body L 4 and a
large tumor manifestation dorsal L5 to S1 (a) of approximately
4.0 × 1.2 cm in the sagittal view accompanied by multiple small
enhancements in the range of the whole spinal cord (a, b).
Figure 4 Sagittal T1-weighted magnetic resonance imaging
images enhanced with gadopentetate dimeglumine, demonstrating
stable disease without evidence of further tumor growth or new
spinal or cranial manifestation 33 months after the first operation
and 12 months after spinal irradiation (a, b).
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mass with an over-all dose of 54 Gy administered in
18 sessions. The cerebellar relapse was treated likewise
with 30 Gy in 5 sessions. Irradiation was combined with
continuous temozolomide chemotherapy (“one week on,
one week off”, 120 mg/day). After therapy the patient
presented in an improved overall condition. She still
described dysesthesia in the lower limbs but showed a
normal function of the bladder and she was also able
to walk without aid.
After radio-/chemotherapy the patient consented to
off-label intravenous bevacizumab antibody-therapy with
15 mg/kg d1 q21d (according 800 mg bevacizumab) com-
bined with a continuous application of temozolomide
100 mg per day over 25 bouts of therapy, administered by
the treating physician team as part of a standard care in
case of disseminated GBM.
This procedure is in consistent with the institutional
ethics committee instructions according to the Federal
Institute for Drugs and Medical Devices. The use is per-
mitted within therapeutic flexibility of the physician in
cases of life-threatening diseases without alternative
therapeutic option and evidence for therapeutic suc-
cess (§35bSGBV).
After 3 months of combined temozolomide/bevacizu-
mab therapy the MRI scans revealed a decrease of cere-
bellar gd - enhancement and a stable clinical condition
concerning the spinal manifestation such as dysesthesia
of the lower limbs.
33 months after the first operation and 12 months
after spinal irradiation the, MRI scans still showed stable
disease without evidence of further tumor growth or new
CNS manifestations [Figure 4] being aware the fact that itis difficult to discriminate the effects of the RT and the ef-
fects of the adjuvant bevacizumab/temozolomide therapy
on the spinal cord. The patient presented in a reduced
nutritional and general condition with dysphagia, vertigo
combined with persistent weakness of the lower limbs,
and atypical pneumonia mainly a result of affected caudal
cranial nerves, which was not seen in the MRI yet. Well-
known side effects under therapy like progressive fatigue
and nausea were also observed, but we also realised a
good toleration of the therapy in haemograms.
The most recent MRI scan, 38 months after the first
operation, revealed a progressive disease with extended
meningeosis carcinomatosa around the brainstem and
the cervical spinal cord. Because of the poor clinical condi-
tion, further chemotherapy and bevacizumab were stopped
in favour of best supportive care.
Brain stem and spinal metastases of supratentorial glio-
blastoma multiforme are well known in the late course of
the disease, but are rarely symptomatic. In a hospital series
of 600 GBM patients, the incidence of symptomatic spinal
metastases was about 2% [12]. To date, the occurrence of
an expophytic cerebellar glioblastoma in combination with
a solid spinal manifestation has not yet been reported.
Fiorentino et al. described combined radiotherapy and
bevacizumab in a case of supratentorial GBM with spinal
manifestation. This patient died 6 months following
diagnosis of metastasis and 3 months after the end of
therapy [13]. No specific data have been published yet
about treatments with bevacizumab of GBM with spinal
manifestation.
A technical enquiry to Hoffmann-La Roche Ltd. Basel
Switzerland by the corresponding author revealed that
there is no data available concerning the bioavailability
of bevacizumab in the cerebrospinal fluid (CSF).
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terior fossa seems to be slightly better than GBM of the
cerebral hemispheres, we confirmed in our case an ab-
sence of IDH -1 mutation, a negative MGMT methylation,
and a meningeosis carcinomatosa as a “signum malum
omnis”. Altogether, these are negative predictors of a good
response to chemotherapy and long overall survival.
On the other hand, an off-label-use of intravenous beva-
cizumab combined with temozolomide and radiotherapy
arrested a further tumor growth at least for 33 months in
the presented case.
Conclusions
Exophytic cerebellar glioblastoma of the posterior fossa
is a rare occurrence. This is also the first report of a
secondary spinal manifestation of this entity.
This report highlights the potential of a combined adjuvant
therapy with bevacizumab to achieve a long-term tumor
control in the case of spinal manifestation of an exophytic
glioblastoma multiforme of the posterior fossa.
Due to the limited overall prognosis of the disease, spinal
manifestations of glioma are rarely clinically relevant.
This is a single case study, thus we cannot postulate this
therapy as standard therapy. The results of our instructive
case, however, with a positive effect on both life quality
and survival warrant treating future patients in the frame
of a prospective clinical study.
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